Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study

Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study

BackgroundMesenchymal Consensus Molecular Subtype 4 (CMS4) colon cancer is associated with poor prognosis and therapy resistance. In this proof-of-concept study, we assessed whether a rationally chosen drug could mitigate the distinguishing molecular features of primary CMS4 colon cancer.MethodsIn t...

Full description

Bibliographic Details
Main Authors: Niek A. Peters, Alexander Constantinides, Inge Ubink, Joyce van Kuik, Haiko J. Bloemendal, Joyce M. van Dodewaard, Menno A. Brink, Thijs P. Schwartz, Martijn P.J.K. Lolkema, Miangela M. Lacle, Leon M. Moons, Joost Geesing, Wilhelmina M.U. van Grevenstein, Jeanine M. L. Roodhart, Miriam Koopman, Sjoerd G. Elias, Inne H.M. Borel Rinkes, Onno Kranenburg
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
consensus molecular subtype 4
imatinib
ImPACCT
platelet-derived growth factor receptor (PDGFR)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.969855/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.969855/full

Similar Items